ArticleThe oncologist2020

Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab.

Takahiro Kogawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.